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Background: Chinese herbal formulae are composed of complex components and produce comprehensive
pharmacological effects. Unlike chemical drugs that have only one clear single target, the components of Chinese
herbal formulae have multiple channels and targets. How to discover the pharmacological targets of Chinese herbal
formulae and their underlying molecular mechanism are still under investigation.
Methods: DanQi pill (DQP), which is one of the widely prescribed traditional Chinese medicines, is applied as an
example drug. In this study, we used the drug target prediction model (DrugCIPHER-CS) to examine the underlying
molecular mechanism of DQP, followed by experimental validation.
Results: A novel therapeutic effect pattern of DQP was identified. After determining the compounds in DQP, we used
DrugCIPHER-CS to predict their potential targets. These potential targets were significantly enriched in well-known
cardiovascular disease-related pathways. For example, the biological processes of neuroactive ligand–receptor
interaction, calcium-signaling pathway, and aminoacyl–tRNA biosynthesis were involved. A new and significant
pathway, arachidonic acid (AA) metabolism, was also identified in this study. This predicted pathway alteration was
validated with an animal model of heart failure (HF). Results show that DQP had effect both on thromboxane B2 (TXB2)
and Prostaglandin I2 (PGI2) in different patterns. It can down-regulate the TXB2 and up-regulate the PGI2 in diverse
way. Remarkably, it also had effect on cyclooxygenase (COX)-1 and COX2 by suppressing their levels, which may be
the critical and novel mechanism of cardiacprotective efficacy for DQP. Furthermore, leukotrienes B4 (LTB4) receptor,
another key molecule of AA metabolism which finally mediated gastrotoxic leukotrienes, was also reduced by DQP.
Conclusions: The combination of drug target prediction and experimental validation provides new insights into the
complicated mechanism of DQP.Background
Heart failure (HF) after myocardial infarction (MI) is a
common clinical syndrome with high morbidity and
mortality [1]. Although traditional risk factors partially
account for the development of HF, other new factors have
recently been implicated. Evidence suggests that inflamma-
tion is important in the development and progression* Correspondence: wangwei26960@126.com
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unless otherwise stated.of HF. Chronic heart failure (HF) is characterized by an
ongoing inflammatory response that correlates with HF
disease severity and prognosis [2]. Given the importance
of inflammatory pathways in HF, new treatment modal-
ities that target inflammatory mediators may be effective.
Recently, a series of experimental studies has reported the
improvement of myocardial infraction and HF through
anti-arachidonic acid (AA) metabolism therapy, specifically
by suppressing cyclooxygenase 1 (COX1) and COX2 [3].
However, these drugs have side effects, such as increased
gastrointestinal and adverse cardiovascular events [4].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HF for thousands of years, and some herbal formulas
have been proved to be effective [5]. Among them, the
ancient DanQi Pill (DQP), prepared from a basic formula
of two Chinese herbs (i.e., Salvia miltiorrhiza and Panax
notoginseng), is widely produced in China in accordance
with the China Pharmacopoeia standard of quality control
[6]. DQP is commonly prescribed in routine treatment
of HF in China. Large-scale randomized and controlled
clinical trials have proved that DQP has a definite effect
in improving heart function [7]. Until now, many stud-
ies are being conducted to investigate the effect of active
monomers in DQP on HF. For example, panax notogin-
seng saponins (PNS, monomer of P. notoginseng) were
found to affect ischemia-induced myocardial apoptosis
[8]; tanshinone IIA (monomer of S. miltiorrhiza bunge)
was found to have cardioprotective effects and to attenu-
ate myocardial hypertrophy [9]. However, most of these
studies examined only one or several pharmacological
effects of the monomer. Studies on the comprehensive
effects of all of the compounds are rare.
In recent years, researchers have developed some bio-
informatic methods to infer drug–target interactions
[10-15], which provide opportunities to conduct more
efficient research on the efficacy of the entire formula.
Recent advances on the databases cataloguing chemical
components of herbs and the interactions between drugs
and targets have contributed to predicting the drug targets
of herbs.
DrugCIPHER-CS is an efficient drug–target prediction
method that was successfully applied to our recent work
[16,17]. In the current paper, we investigated the pharma-
cological mechanism of DQP using DrugCIPHER-CS to
predict drug targets, followed by experimental validation.
Specifically, after obtaining the potential targets of DQP,
the significantly enriched Kyoto Encyclopedia of Genes
and Genomes (KEGG) biological pathways and Gene
Ontology (GO) biological processes involved in these
potential targets were analyzed. AA metabolism pathway
was selected to elucidate the special efficacy patterns of
DQP. This study applied novel and effective methods
and provided insight into the complicated multi-targets
mechanism of herbs.
Methods
Drug–target prediction and analyses
We used DrugCIPHER-CS to predict the drug targets of
the main compounds of DQP, following the procedure
described in [17]. The herbal compounds were first
identified in the Modern Chinese materia medica data-
base [18]. The identified compounds were then typed
into the durgbank (http://www.drugbank.ca/) to search
their structural information including their canonical
and isomeric SMILES. Then we applied DrugCIPHER-CSto predict the potential drug targets of these compounds.
DrugCIPHER-CS achieved good prediction performance
in our previous study and can infer drug-targets in the
genome-wide scale [17]. This method is based on the
hypotheses that i) drugs with similar chemical struc-
ture usually bind functionally related proteins, and ii)
functional relationship between the proteins can be
measured by their distance in the protein interaction
network. Given a set of known drug (drug space)-tar-
get (target space) interactions, for a query drug and a
candidate target-gene, drugCIPHER-CS will measure
the likelihood of their interaction based on the correlation
between the query drug’s structure similarity vector with
the drug space and the candidate gene’s functional similar-
ity vector with the target space. For a query compound,
drugCIPHER-CS will prioritize the proteins in the protein
interaction network (i.e. candidate proteins) according
to the order of the decreasing drug-target interaction
likelihood, and the candidate proteins with high likelihood
will be hypothesized as the potential drug-targets [16].
Here known drug-target interactions are obtained from
DrugBank database [19]. We only use those drug-target
interactions whose drugs are FDA-approved and have
InChI identifiers [20]. The chemical structure similarity
is calculated based on compounds’ MOLPRINT 2D de-
scriptors and Tanimoto coefficient [21].
After obtaining the potential drug targets, we analyzed
the significantly enriched KEGG biological pathways and
GO biological processes of these potential targets using the
hypergeometric cumulative distribution test [22]. A path-
way was significantly enriched with candidate target-genes
when its corresponding upper-tailed P-value of hypergeo-
metric cumulative distribution was smaller than 0.05.
The pathways were ranked according to the order of the
increasing P-values. Then, GO annotations of human
proteins were obtained from the GO project Web site
(http://www.geneontology.org/) [23]. The top 0.1% candi-
date target-genes were significantly enriched with genes
annotated with a GO term when its corresponding upper-
tailed P-value of hypergeometric cumulative distribution
was smaller than 0.05. These GO terms were ranked ac-
cording to the order of the increasing P-values. KEGG
biological pathway data were downloaded from the KEGG
database [24].
HF model preparation and grouping
Studies were performed in accordance with the China
Physiological Society’s “Guiding Principles in the Care and
Use of Animals” and with approval of the Animal Care
Committee of Beijing Medical Center (SCXK: 2006-0009).
A total of 80 male Specific Pathogen Free (SPF)-grade
Sprague–Dawley (SD) rats weighing 240 ± 10 g were se-
lected (purchased from Beijing Vital River Laboratory
Animal Technology Co. Ltd.). HF was induced by direct
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sixty SD rats were anaesthetized with pentobarbital sodium
(1%, 50 mg kg − 1 intraperitoneally). The left anterior
descending coronary artery (LAD) was ligated with a 5–0
polypropylene suture (Surgipro, CT, USA) directly prox-
imal to its main branching point. After electrocardiograph
testing, rats that averaged QT-interval prolongation in
three pre-cordial leads were included in the study. Sham-
operated groups of the rest twenty rats were prepared fol-
lowing an identical procedure, but without the actual tying
of the polypropylene suture. The overall mortality of rats
that underwent induction of HF during the entire experi-
mental period (up to 28 days after operation) was 30%.
The majority of death occurred on the day of or the day
after the surgery, probably because of acute pump failure
or lethal arrhythmias. The operated rats were then ran-
domly divided into two groups: 20 in the model group, 20
in the DQP group. Meanwhile, 20 in sham-operated group
were investigated together. The rats were fed with a stand-
ard diet and water, and were maintained on a 12 h light
and dark cycle. The DQP group was treated for 28 days,
with the total daily dosage of 1.5 g/kg of the concentrated
DQP (Tongren Tang, Beijing, China) dissolved in water.
The sham and model groups received the same volume of
water through oral gavage as the DQP vehicle. At the end
of the study, all animals were anaesthetized using pento-
barbital sodium following an overnight fast. Blood samples
were collected through abdominal aorta puncture and
were placing on ice. After centrifugation, plasma was col-
lected, aliquoted, and stored at -80°C until analysis of each
indicator. The heart was excised and incubated in ice-cold
PBS to wash out blood. Each left ventricle was then care-
fully dissected to remove all the necrotic/scarred zones to
keep only the viable myocardium in the marginal zone of
the infarct region in model animals. The left ventricular
myocardial below ligation bit in sham animals were also
dissected.
Echocardiographic assessment of the left ventricle
(LV) function
Echocardiography was used to detect left ventricle (LV)
end-systolic diameter (LVEDs), LV end-diastolic diameter
(LVEDd), ejection fraction (EF) and fractional shortening
(FS). A sector scanner (PST 65A, Toshiba Company, Japan),
which generates two-dimensional images at a frame rate
of 300 frames/s to 500 frames/s, was used. Fractional
shortening (FS%) was calculated by the following equation:
FS% = [( LVEDd- LVEDs)/LVEDd]*100%.
Preparation and dose consideration of concentrated DQP
The DQP (Series: 6128006) used in this study was man-
ufactured by Tongrentang company (Beijing, China) with
the roots of 150 g S. miltiorrhiza and 150 g P. notoginseng.
Briefly, the residue of P. notoginseng was mixed with all S.miltiorrhiza bunge, followed by extraction with hot water
(twice at 2 h each). The water extract was then concen-
trated to form a paste, and ethanol was added. After 24 h,
the filtrate, which was the final product, was collected.
Based on the recommendation of daily human dosage
(20 g/d) and the equivalent conversion between animal
and people by body surface area and body weight, dosage
of 1.5 g/kg was chosen in the present study.Measurement of plasma indicators by Enzyme Linked
Immunosorbent Assay (ELISA)
Levels of plasma indicators were quantified in duplicate
using commercial ELISA kits (Abcam Inc., Cambridge,
MA, USA). Each assay was performed following the kits’
instructions. Standards at a series of concentrations were
run parallel to the samples. The concentrations of the sam-
ples were calculated in reference to their corresponding
standard curves and expressed as ng/mL.Measurement of indicators by Western blot
The heart tissue was homogenized in RIPALYSIS buffer
(i.e., 50 mM Tris-HCl pH7.4, 150 mM NaCl, 2 mM
EDTA, 1% NP-40, and 0.1% SDS), and total protein was
extracted from this homogenate. The protein concen-
tration in each extract was measured using a protein
assay kit (Pierce; Rockford, IL) and was then adjusted to
the same value in all samples with 2× 4% Sodium dodecyl
sulfate (SDS) sample buffer. The samples were boiled for
5 min, followed by loading on a 12.5% SDS-Polyacrylamide
gel electrophoresis (PAGE) gel (30 mg protein/10 ml
per well) for electrophoresis using a Bio-Rad mini gel
apparatus at 100 V for 2 h. The fractionated protein on
the gel was transferred onto an NC membrane (Millipore)
and electrophoresed at 300 mA for 90 min. The mem-
brane was first probed with COX1 primary antibody
(anti-COX Type 1 antibody, ab18801, Abcam, 1:500)
and secondary antibody (donkey polyclonal secondary
antibody to rabbit IgG-HRP,ab97064, Abcam, 1:5000),
and then treated with ECL (ECL plus Western blotting
detection reagent, GE Healthcare) for 1 min at room
temperature. The bands in the membrane were visual-
ized and analyzed using UVP BioImaging Systems.
After obtaining the COX1 blot density, the membrane
was then treated using Restore Western Blot Stripping
Buffer (Thermo Scientific) to remove the COX1signal,
followed by probing with glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) primary antibodies (GAPDH
mouse monoclonal IgG, ab8245, Abcam, 1:2000). The
COX2, prostaglandin E2 receptor 4 (EP4), and leuko-
trienes B4 receptor (LTB4R) antibody blot densities
were determined using the same process. The final re-
ported data were the normalized COX1 band densities
by GAPDH.
Table 2 Significantly enriched GO biological processes
among top 0.1% candidate target-genes of DQP composi-
tive compounds
GO term ID Description P-valuea
GO:0009058 Biosynthetic process 9.37E-09
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ANOVA using SAS 9.2 statistical software (SAS Institute,
NC, USA) was applied to evaluate between-group differ-
ences in the outcome variables, follow-up least significant
differences (LSD) analysis verified these differences were
significant. P < 0.05 was considered statistically significant.
Results were presented as mean values with their corre-
sponding standard deviations.
Results
Drug target prediction and analyses
Through a comprehensive search, we collected 92 com-
pounds of DQP with 50 and 42 in Danshen and Sanqi re-
spectively. The DrugCIPHER-CS method [17] was used to
infer the potential targets of the compounds (see Methods).
For each of the compound of DQP, DrugCIPHER-CS
ranked its candidate targets according to the order of
decreasing possibility of being targeted by the compound.
We chose the top 0.1% candidate targets of each compound
and consequently obtained 232 candidate target genes.
These candidate targets were significantly enriched as
known cardiovascular disease-related genes (i.e., the
known targets of drugs whose ACT code uses “C” as the
first level) in DrugBank [16], consistent with the curative
effect of DQP on cardiovascular disease.
Furthermore, we analyzed the enriched KEGG biological
pathways among these potential targets. Seven significantly
enriched pathways among the top 0.1% candidate targets
were analyzed, including the pathways of neuroactive
ligand–receptor interaction, AA metabolism, calcium-
signaling pathway, aminoacyl-tRNA biosynthesis and
renin-angiotensin system (RAAS) et al. (Table 1). These
significantly enriched biological pathways provided im-
portant information on the mechanism of DQP. Many ofTable 1 Significantly enriched KEGG biological pathways
among top 0.1% candidate target-genes of DQP compositive
compounds




Path:hsa04020 calcium signaling pathway 5.22E-06 7.30
Path:hsa04614 renin-angiotensin system 5.64E-06 9.41
Path:hsa00970 aminoacyl-tRNA biosynthesis 4.67E-05 14.63
Path:hsa00250 alanine, aspartate and
glutamate metabolism
1.29E-04 16.13
Path:hsa00590 arachidonic acid metabolism 2.46E-03 18.62
Path:hsa00330 arginine and proline
metabolism
1.15E-02 7.41
aA pathway is significantly enriched with candidate target-genes when its
corresponding upper-tailed P-value of hypergeometric cumulative distribution is
smaller than 0.05. The pathways are ranked according to the order of the
increasing P-values. bThe coverage for each pathway is referred to as the
fraction of candidate target-genes among all the pathway member genes.these enriched pathways have been associated with HF,
e.g., the importance of neuroactive ligand–receptor inter-
action in the development and progress of cardiovascular
diseases [26]. The key proteins in this pathway, such as
adrenergic, angiotensin, and calcitonin receptor-like neu-
rotensin receptors, are closely related to cardiac function
[27-29]. Aminoacyl-tRNA biosynthesis pathway is import-
ant in cardiovascular angiogenesis [30]. The relationship
between calcium-signaling pathway and HF was also iden-
tified in the present study. Calcium antagonists have been
widely used to inhibit extracellular calcium influx, reduce
the concentration of intracellular calcium, and lower
myocardial contractility [31]. Upregulation of the renin–
angiotensin system is crucial in the deterioration of car-
diovascular function [32]. However, the AA metabolism
was rarely investigated both in HF and in DQP’s efficacy,
it showed a significant difference as well as the pathway
coverage in our study.
We also analyzed the functional distribution of these
candidate targets (Table 2). The significantly enriched GO
biological processes of these targets are cellular amino
acid metabolic process, biosynthetic process, small mol-
ecule metabolic process, cellular nitrogen compound
metabolic process, and circulatory system process, which
suggest that the DQP may intervene in these progresses.
These enriched pathways and GO functional annotations
provided important clues to the molecular mechanism
of DQP.GO:0006520 Cellular amino acid metabolic process 3.27E-08
GO:0034641 Cellular nitrogen compound metabolic process 3.56E-07
GO:0071941 Nitrogen cycle metabolic process 1.53E-05
GO:0006399 tRNA metabolic process 7.32E-05
GO:0044281 Small molecule metabolic process 1.16E-04
GO:0003013 Circulatory system process 1.43E-03
GO:0007267 Cell-cell signaling 3.33E-03
GO:0006950 Response to stress 3.63E-03
GO:0006412 Translation 9.13E-03
GO:0042592 Homeostatic process 1.19E-02
GO:0007568 Aging 1.60E-02
GO:0050877 Neurological system process 1.63E-02
GO:0008283 Cell proliferation 2.55E-02
GO:0008219 Cell death 4.09E-02
aThe top 0.1% candidate target-genes are significantly enriched with genes
annotated with a GO term when its corresponding upper-tailed P-value of
hypergeometric cumulative distribution is smaller than 0.05. These GO terms
are ranked according to the order of the increasing P-values.
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Twenty-eight days after surgery, the EF and FS values
of rats in the model group were significantly lower
than those of the sham group, as indicated by echocar-
diography (P < 0.05, Figure 1). EF values of ligation rats
in model group dropped compared with those of the
sham group, which suggested that a steady HF model
was established. Twenty-eight days after treatment
with DQP, EF values in the treatment group increased
compared with those in the model group (Figure 1,
Table 3).
Effects of DQP on myocardial fibrosis
The MASSON images of the left ventricular tissue were
shown in Figure 2. Cardiomyocytes in the sham group
were orderly arranged. Thickening and lengthening of
myocardial fibers were observed in the model group.
The nuclei were stained dark, which indicated local tissue
fibrosis in the model group, while DQP had the inhibitory
effect on ventricular hypertrophy.
Validation of the predicted target pathways
Neurohormonal activation is important in the development
of cardiovascular disease such as HF. However, the role
of AA metabolism in HF development is still not clear
[33]. Some studies show that inflammatory cells can re-
lease AA, which may be further metabolized into activeFigure 1 The cardiac function in different groups. Cardiac function det
LVEF and LVFS in sham-operated group. (B) Down-regulation of LVEF and
and FS. A: sham group; B. model group; C. DQP group.products mediating cardiac fibrosis and HF. Some of the
metabolic products, such as prostacyclin, are considered
potential therapeutic targets of HF [34]. In the current
study, the alteration of the AA metabolism pathway in
HF was identified by DrugCIPHER-CS prediction and
validated in animal models.
Western blot results showed that COX1 level in the
model group (0.79 ± 0.096) increased 28 days after oper-
ation compared with that in the sham group (0.45 ± 0.01)
(P = 0.031, Figure 3). After treatment with DQP, COX1
level in the DQP group (0.39 ± 0.08) decreased compared
with that in the model group (P = 0.017). COX1 level
in DQP-treated group showed no significant difference
compared with that in the sham group (P = 0.896).
COX2 level in the model group (1.213 ± 0.095) increased
compared with that the sham group (0.409 ± 0.027) (P =
0.000). The level of COX2 in the DQP group (0.58 ±
0.057) decreased compared with that in the model group
(P = 0.011) 28 days after treatment, recovering almost to
sham group level.
Furthermore, LTB4 receptor (LTB4R) level in the model
group (0.89 ± 0.113) was upregulated compared with
that in the sham group (0.271 ± 0.098) (P = 0.000).
Twenty-eight days after treatment with DQP, LTB4R
level in the DQP-treated group (0.41 ± 0.106) decreased
significantly compared with that in the model group
(P =0.003, Figure 4).ected by echocardiography. (A) Normal cardiac function including
LVFS in model group rats. (C) DQP can significantly up-regulate the EF
Table 3 Echocardiographic changes observed in different groups (x ± s)
Group Sham Model DQP P value
LVEDd (cm) 0.74 ± 0.047** 1.05 ± 0.107▲▲ 0.95 ± 0.128▲▲ 0.001
LVEDs (cm) 0.35 ± 0.055** 0.85 ± 0.078▲▲ 0.70 ± 0.203▲▲* 0.000
FS 52.47 ± 5.423** 18.71 ± 1.675▲▲ 28.07 ± 11.879▲▲ 0.025
EF 87.41 ± 4.271** 42.86 ± 3.110▲▲ 57.38 ± 18.519▲▲** 0.017
Cardiac function was detected by echocardiography. Normal cardiac function was found in sham-operated group including LVEDd, LVEDs, LVEF and LVFS.
Down-regulation of cardiac function appeared in model group rats. DQP can significantly up-regulate the EF and FS, and reduced the LVEDs. ▲▲P < 0.01, vs
sham- operated group; *P < 0.05, **P < 0.01, vs model group.
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sidered better targets with protective effects in curing
HF. Especially receptor 4 of PGE2, E-series prostanoid
receptor 4 (EP4), is currently emerging as most versatile
and promising among PGE2 receptors, and the PGE2/EP4
signalling is thought to be the potential targets to HF and
myocardial ischemia [35]. In our study, EP4 of model
group (0.14 ± 0.058) was down-regulated compared with
that in the sham group (0.28 ± 0.052) (P = 0.023). In the
DQP group, the EP4 level (0.26 ± 0.061) increased com-
pared with that in the model group (P = 0.031), which had
no significant difference with the sham group (Figure 4).
Prostacyclin I2 (PGI2) and thromboxane A2 (TXA2) are
the products of AA metabolism through the COXs
pathway. PGI2 has a cardioprotective effect by inhibiting
platelet aggregation, whereas TXA2, which is quickly me-
tabolized to TXB2, increases the risk of cardiovascular
events [36]. In our study, ELISA results showed that levels
of 6-Keto-PGF1α, which is the stable metabolite of PGI2,
in the model group decreased compared with that in the
sham group (P = 0.036). DQP upregulated 6-Keto-PGF1α
levels in the model group almost back to normal conditionsFigure 2 Masson results in different groups. (A) Cardiomyocytes in the
myocardial fibers were observed in the model group. The nuclei were stain
inhibitory effect on ventricular hypertrophy. A: sham group (×100); B. mod
group (×400); F. DQP group (×400).28 days after administration. TXB2 is the product of TXA2
and can therefore reflect the level of TXA2 in plasma. The
level of TXB2 increased in the model group. Although
DQP showed no significant effect on TXB2, DQP increased
the 6-Keto-PGF1α-to-TXB2 (P/T) ratio (Table 4).
Discussion
In the present study, drug target prediction was applied to
reveal the underlying mechanism of DQP. A potential
target pathway seldom studied, AA metabolism, was
investigated. After experimental validation, COXs and
LTB4 were determined to be the targets of DQP.
Both nonselective and COX-specific inhibitors called
nonsteroidal anti-inflammatory drugs are commonly used
in relieving pain associated with medical conditions [37].
COX (prostaglandin G/H synthase) is a key enzyme in
prostaglandin synthesis; it has two isoforms (i.e., COX1
and COX2) [38]. COX1 is constitutively expressed and
is probably responsible for prostaglandin release under
physiological conditions, and COX2 is expressed at high
levels upon induction. COX activation produces prosta-
glandin H2, which is subsequently converted to PGE2,sham group were orderly arranged. (B) Thickening and lengthening of
ed dark, which indicated local tissue fibrosis. (C) DQP had the
el group (×100); C. DQP group (×100); D: sham group (×400); E. model
Figure 3 DQP regulates COX1 and COX2 in HF rats significantly. The results showed that in model group, COX1 and COX2 concentration
was significantly higher than that in sham-operated group. In DQP group, level of COX1 and COX2 were decreased significantly. *P < 0.05,
**P < 0.01, vs model group.
Figure 4 Westernblot results of LTB4R and PGE2 receptor in different groups. The results showed that in model group, LTB4R concentration
significantly increased than that in sham-operated group. In DQP group, it was decreased significantly. While PGE2 receptor-EP4, in the model group
decreased compared with that in the sham-operated group, and it was up-regulated by DQP in DQP group. *P < 0.05, **P < 0.01, vs model group.
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Table 4 Levels of 6-Keto-PGF1α and TXB2 in different groups
Group Sham Model DQP P value
6-Keto-PGF1α (pg/ml) 240.09 ± 77.365* 78.33 ± 39.043▲ 230.89 ± 85.021* 0.016
TXB2 (pg/ml) 88.53 ± 9.139* 271.01 ± 156.103▲ 168.31 ± 104.670 0.033
Ratio of P/T 1.81 ± 0.839* 0.81 ± 0.481▲ 1.47 ± 0.688* 0.024
The results showed that in model group, concentration of TXB2 significantly increased than that in sham-operated group. In DQP group, it was decreased.
6-Keto-PGF1α in the model group decreased compared with that in the sham-operated group, and it can be up-regulated by DQP. *Mean values were significantly
different from model (*P < 0.05), ▲Mean values were significantly different from sham (▲P < 0.05).
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TXA2 are unstable in plasma, and quickly metabolized
to 6-Keto-PGF1α and TXB2 respectively [39]. Imbalance
between TXA2 and PGI2 is considered as a critical cause
of HF. Anti-COXs therapy with aspirin, which at low
doses acts as a selective inhibitor of COX activity, is well
established. However, a major limitation of aspirin treat-
ment is its gastrointestinal toxicity, which is considered
linked to its disruption of the balance between TXA2 and
PGI2. Newly developed dual COX2 and LTB4 inhibitors
not only share the anti-inflammatory effect of COX1
inhibitors but also inhibit the 5-lipoxygenase (LOX)-
mediated synthesis of gastrotoxic leukotrienes. Dual
inhibitors may be beneficial in the treatment of HF with
fewer side effects [40].
In the present study, using DrugCipher-CS software,
AA metabolism was predicted to be altered by DQP. An
experiment using an animal model validated that the
alteration of the levels of proteins in the AA metabolism
pathway with the occurrence of HF and administration
of DQP to HF rats could suppress these protein levels.
Consistent with previous reports, the LAD-induced HF
animals were characterized by declined diastolic and
systolic myocardial performance (i.e., decreased EF and
FS values) and myocardial fibrosis. Our results also
agree with those of previous studies that demonstrate
the enhanced activation of cardiac AA metabolism in
HF, such as PGI2 and TXB2 [41]. Moreover, COXs and
LTB4 are the products of two AA metabolism pathways
mediated by COX and LOX, respectively. Levels of COXs
and LTB4R increased in HF models because of the activa-
tion of AA metabolism.
DQP treatment was able to regulate the AA metabolism
in different ways. First, COX1 and COX2 are downregu-
lated, thus suppressing AA activation and avoiding its
gastrointestinal toxicity. Downregulation of LTB4R also
occurs. LTB4 produced from AA by 5-LOX is a potent
chemo-attractant of leukocytes [42]. Therefore, the car-
dioprotective effect on HF by DQP is partly due to its
inhibition of LTB4R. These results also support the
emerging role of inflammation in the development and
progression of HF [33,43].
PGI2 and TXA2 belong to metabolites of AA pathway,
and they have critical and contradictory roles in theprogression of HF. PGI2 exhibits cardioprotective effects
by inhibiting the aggravation of HF. However, TXA2,
which is metabolized into TXB2, increases the risk of
cardiovascular events. The dynamic balance between
the metabolites is considered a critical biomarker of
thrombosis regulation in HF [44]. Although DQP cannot
directly reduce the concentration of TXB2, DQP can
significantly upregulate the cardioprotective PGI2 and
recover the imbalance of P/T ratio, thus providing a
synthetic effect on HF.Conclusions
Our results suggest that DQP exerts a synthetic cardiac
protective role by targeting multiple targets in the treat-
ment of HF. Particularly, DQP can attenuate the activation
of AA metabolism in HF by reducing the levels of COXs
and LTB4R while increasing the levels of PGE2 receptor
EP4 and PGI2. The combination of drug target prediction
and experimental validation provides new insights into the
complicated mechanism of DQP in the treatment of HF.Limitations
There are some limitations in our study. For example,
the search for DQP compounds has been done through the
Chinese Materia Medica only, which is far from compre-
hensive. We presume all components of herbal formulation
compounds are absorbed and utilized; improvement should
be made in our future work.
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